CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID‐19 therapy

• Published in: Journal of medical virology Vol. 95; no. 1; pp. e28427 - n/a
• Main Authors: Machado, Thiago L., Santos, Alanna C., Azamor, Tamiris, Silva, Andrea M. V., Pimenta, Vanessa R., Tubarão, Luciana N., Silva, Alexandre dos Santos, Flores Rodrigues, Daniela Del Rosário, Müller, Rodrigo, Pinto, Marcelo A., Villar, Livia M., Bom, Ana P. A., Melgaço, Juliana G.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.01.2023
• Subjects: Antibodies, Monoclonal; Bacterial diseases; Binding sites; Cell activation; CLEC5A; CLEC5A protein; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Cytokines; Gene expression; Glycoproteins; Hamsters; Humans; Immune response; Immune system; Immunology; immunotherapy; Infections; Inflammation; Lectins, C-Type - genetics; Leukocytes (neutrophilic); Molecular interactions; Monoclonal antibodies; Monocytes; N-Acetylglucosamine; Receptors; Receptors, Cell Surface - genetics; Respiratory diseases; Respiratory function; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Spike glycoprotein; Spike Glycoprotein, Coronavirus; spike protein; Vaccines; Viral diseases; Virology; COVID-19; monocytes; CLEC5A; immunotherapy; spike protein

The immune response is crucial for coronavirus disease 19 (COVID‐19) progression, with the participation of proinflammatory cells and cytokines, inducing lung injury and loss of respiratory function. CLEC5A expression on monocytes can be triggered by viral and bacterial infections, leading to poor o...